---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-26-000188"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2026-08-05T20:04:32+00:00"
generated_at: "2026-08-05T20:05:08.241847+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q2 revenue $12.0M (+18% YoY), net income $0.25M, raises gross margin guidance to 62-64%

## Summary
- Net revenues $12.0M (+18% YoY); gross profit $7.8M (+20%); gross margin 65.1% vs 63.5% prior year.
- Net income $0.25M vs net loss ($0.2M) prior year; adjusted EBITDA $0.9M vs $0.3M.
- Updated FY2026 guidance: revenue $47.5-$48.5M (15-18% growth), gross margin 62-64%, positive adjusted EBITDA, year-end cash >$7.5M.
- Acquired connected monitoring technology asset; withdrew 510(k) for FreedomEDGE with Phesgo in U.S., shifting oncology strategy to higher volume molecules.
- Entered multi-year supply agreement; cash $8.3M at quarter end.

## SEC filing metadata
- accession: 0001161697-26-000188
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2026-08-05T20:04:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169726000188/0001161697-26-000188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169726000188/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-26-000188
- JSON: https://secwatch.observer/filing/0001161697-26-000188.json
- Plain text: https://secwatch.observer/filing/0001161697-26-000188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.